Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by United Asset Strategies Inc.

United Asset Strategies Inc. boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 14.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,123 shares of the medical research company’s stock after acquiring an additional 1,142 shares during the quarter. United Asset Strategies Inc.’s holdings in Edwards Lifesciences were worth $696,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after purchasing an additional 325,808 shares during the period. Alliancebernstein L.P. increased its position in shares of Edwards Lifesciences by 0.3% during the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock valued at $1,934,919,000 after purchasing an additional 66,763 shares during the period. Wellington Management Group LLP increased its position in shares of Edwards Lifesciences by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the period. Moneta Group Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after acquiring an additional 15,384,593 shares in the last quarter. Finally, Brown Advisory Inc. boosted its stake in shares of Edwards Lifesciences by 5.7% during the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after acquiring an additional 818,849 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the subject of several research reports. Evercore ISI raised their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a research note on Friday, February 2nd. Finally, Truist Financial raised their target price on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Trading Up 1.0 %

Edwards Lifesciences stock opened at $90.06 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The business’s 50-day simple moving average is $90.11 and its 200-day simple moving average is $78.07. The firm has a market capitalization of $54.21 billion, a PE ratio of 39.16, a PEG ratio of 4.42 and a beta of 1.05. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period last year, the business earned $0.64 earnings per share. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last three months. 1.27% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.